Cultivated Meat Cell Lines & Media Patents: Leaders & Gaps 2026
- Concentrated at the top. The top 5 assignees hold 203 records — 47.1% of all 431 in scope — while a long tail of single-filing entrants fills out the rest of the 89-company ranking.
- Filings accelerated sharply, then the record thins as expected. Filings rose from 1 in 2021 to 11 in 2024, a +1000% increase over that span; 2025-2026 figures are still filling in due to publication lag.
- Claim density sits almost entirely in genetic engineering. C12N covers 81.2% of the 431 records, meaning bioreactor and downstream processing classes such as C12M remain comparatively open.
Filing growth compares 2021 (1 records) with 2024 (11) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 431 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent families addressing cultivated meat cell lines and serum-free culture media — filings that combine myoblast proliferation, growth factor cost reduction, media recycling, immortalized line development, food-grade component substitution and doubling-time claims. The scope spans 431 published records filed or published between 2015 and mid-2026, drawn from a search string that pairs cell-line and medium terms with the specific technical levers used to make cultivation commercially viable.
Most records in this set originated as biomedical or vaccine-production patents before the cultivated meat sector adopted the same serum-free, cost-reduced culture techniques, which explains why several of the most-cited documents in the corpus concern influenza vaccine production rather than food. That lineage matters for freedom-to-operate work: broad serum-free medium and myoblast proliferation claims filed for pharmaceutical or veterinary purposes can still read onto a cultivated meat process.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 431-record set: how filing activity has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017-2026
Filings peaked at 31 in 2017, the corpus's high point so far. Activity then dropped before rebuilding: 2021 recorded 1 filing and 2024 recorded 11, a +1000% increase over that three-year span. 2025 and 2026 numbers are undercounted because publication typically lags filing by around 18 months, so the apparent decline in the newest years should not be read as slowing interest.
IPC subclass composition
C12N (microorganisms and genetic engineering) appears in 81.2% of the 431 records, far ahead of A61K medicinal preparations at 41.1%. Bioreactor and apparatus class C12M sits at just 4.9%, and enzymatic measuring/testing (C12Q) at 7.0% — both comparatively thin given how central scale-up equipment and quality-control assays are to commercial viability. A record can carry multiple classes, so these figures sum to more than 100%.
Shares are the percentage of the 431 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cultivated Meat Cell Lines and Media with Eureka
This page is one run against one query. Ask Eureka your own question about cultivated meat cell lines and media and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in the corpus
US6033660A — Method of treating a nervous system injury with cultured Schwann cells
The patent discloses a method for enhancing survival and proliferation of Schwann cells in culture using a serum-free medium formulated with gas6 and mitogenic agents including heregulin and forskolin, preceded by a demyelination pre-incubation step. The isolated cells are proposed for use as cellular prostheses in nervous-system injury treatment. The filing also claims the serum-free culture medium itself as a composition.Filed by Genentech, granted 2000-03-07 — illustrates how early serum-free medium composition claims from biomedical cell culture work can extend into food-grade cultivation processes.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5858368A | Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein | 416 |
| 2 | US5762939A | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus | 401 |
| 3 | WO2017197347A1 | Methods for selective expansion of γδ t-cell populations and compositions thereof | 123 |
| 4 | WO1996037624A1 | A method for producing influenza hemagglutinin multivalent vaccines | 120 |
| 5 | US6245532B1 | Method for producing influenza hemagglutinin multivalent vaccines | 99 |
| 6 | US20140242693A1 | Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells | 93 |
| 7 | US20150125950A1 | Umbilical cord mesenchymal stem cell exosomes | 89 |
| 8 | WO2011058558A2 | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state | 81 |
| 9 | US6033660A | Method of treating a nervous system injury with cultured schwann cells | 63 |
| 10 | WO2013172793A1 | Umbilical cord mesenchymal stem cell exosomes | 61 |
Citation counts reward older filings that have had more time to accumulate references within this searched corpus — treat them as a signal of influence on the field's vocabulary and claim structure, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing strategy
Three read-outs from the concentration, growth and composition figures above, translated into what they imply for anyone deciding where to file or license.
The top of the field is tight, the rest is scattered
With 203 of 431 records sitting among five assignees and the ranked list running to 89 companies total, the field has a small group of entities whose claims any freedom-to-operate review must clear first, followed by a long tail of one- and two-filing entrants.
Activity rebuilt fast after a lull
Filings fell to 1 in 2021 before climbing to 11 by 2024. That trajectory signals renewed commercial interest in cultivation-specific claims rather than a maturing, saturated space — the growth is recent enough that many claim boundaries are still being tested rather than settled.
Genetic engineering claims dominate; hardware claims are thin
C12N (microorganisms and genetic engineering) appears in the large majority of records, while C12M (bioreactors and apparatus) sits at only 4.9% and C12Q (enzymatic/DNA testing) at 7.0%. Process and hardware-side claims around scale-up, recycling and quality assays look comparatively under-filed relative to cell-line and medium composition claims.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cultivated meat cell lines and media, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Agency for Science, Technology and Research (A*STAR) | SingHealth Services Pte Ltd | 12 |
| Agency for Science, Technology and Research (A*STAR) | LIM SAI KIANG | 5 |
| Technion Research & Development Foundation Ltd. | ITSKOVITZ ELDOR JOSEPH | 2 |
| Technion Research & Development Foundation Ltd. | AMIT MICHAL | 2 |
| Agency for Science, Technology and Research (A*STAR) | TAN KOK HIAN | 2 |
| MULTICELL TECH | LIU JIN | 2 |
| MULTICELL TECH | FARIS RONALD A | 2 |
| Adicet Bio, Inc. | Adicet Therapeutics, Inc. | 1 |
The corpus records 10 co-assignee pairs, with the strongest pairing appearing 12 times — evidence that institutional and corporate co-development, rather than solo filing, produced some of the field's more heavily cross-referenced claims.
Who is filing, and where the gate sits
The leader in this ranking holds 84 records; fifth place holds 19 and tenth place holds 12 — a steep drop-off that defines where a new entrant's claims would actually compete for space.
A single assignee dominates the ranked list
The top-ranked assignee's record count is more than four times the fifth-place figure, indicating a deep, defensible claim position built over years rather than a recent land grab.
A second tier holds meaningful but contestable ground
Places two through five hold enough volume to matter in a freedom-to-operate search but not enough to foreclose adjacent claim variations, particularly outside core medium-composition language.
Several established filers show no recent activity
A number of the historically largest assignees register zero filings in the latest tracked year, which given publication lag may reflect pending applications not yet published rather than exits from the space.
| Assignee | Recent year | YoY |
|---|---|---|
| BTL Healthcare Technologies a.s. | 1 | -75% |
| Janssen Biotech, Inc. | 0 | — |
| Technion Research & Development Foundation Ltd. | 0 | — |
| Agency for Science, Technology and Research (A*STAR) | 0 | — |
| MG-PMC Co., Ltd. | 0 | — |
| Protein Sciences Corporation | 0 | — |
| Adicet Bio, Inc. | 0 | — |
| Genentech, Inc. | 0 | — |
Where to take this next
The figures above establish where claim density sits; the next step is narrowing to the specific process step or medium component a given project depends on.
Map a specific claim against the leader's portfolio
Before filing on a medium composition or proliferation method, check it against the top-ranked assignee's 84 records rather than the field average — that is where overlap risk concentrates.
Explore assignee portfolios in EurekaTrack the under-claimed hardware side
C12M's 4.9% share suggests bioreactor and apparatus claims are thinner than the biology; a scale-up-specific filing may face less prior art than a medium-composition one.
Run a white space search in EurekaCommon questions on this landscape
The ranked list in this dataset covers 89 companies, and it is concentrated: the leading assignee holds 84 of the 431 records in scope, with the top 5 combined holding 203 records, 47.1% of the total. Beyond the top 10, which together hold 62.4% of records, filing activity thins into a long tail of assignees with only one or two records each. This means freedom-to-operate review should prioritise the handful of dominant filers before worrying about the tail.
Filings grew sharply in the recent complete years, rising from 1 in 2021 to 11 in 2024, a +1000% increase over that span. The overall trend also shows a much older peak of 31 filings in 2017, reflecting earlier biomedical and vaccine-production activity that predates the cultivated meat sector's adoption of the same techniques. Figures for 2025 and 2026 understate real activity because publication typically lags filing by about 18 months, so those years should not be read as a slowdown.
The most heavily cited record in this corpus, US6033660A, claims a serum-free culture medium formulated with specific growth and mitogenic factors alongside a method for using it on a particular cell type, and similar composition-style claims recur across the top-cited documents in the set. Because C12N classifications cover 81.2% of the 431 records, most of the crowded claim space concerns genetic engineering and cell-line composition rather than downstream processing. Anyone drafting new medium claims should expect dense prior art around growth-factor combinations specifically, less so around bioreactor integration.
The clearest gaps sit in classes with low record shares relative to their commercial importance: C12M (bioreactors and apparatus) appears in only 4.9% of the 431 records and C12Q (enzymatic and DNA-based testing) in 7.0%, both well behind the 81.2% carried by core genetic-engineering claims. Practically, this points to media recycling, in-line doubling-time monitoring and food-grade component substitution as under-claimed relative to medium-composition and cell-line claims. These are process and hardware areas, not biology, which is why they show up thin despite being essential to scaling production.
Yes — several of the most-cited records in this dataset, including vaccine-production patents using baculovirus-expressed proteins, were filed for pharmaceutical purposes but claim serum-free culture medium and cell proliferation methods broadly enough to potentially cover food-grade cultivation processes. This cross-over lineage is visible in the IPC composition, where A61K medicinal preparations appears in 41.1% of the 431 records despite the search targeting cultivated meat terms specifically. Any clearance search for a cultivated meat medium or cell-line process should therefore include biomedical and veterinary prior art, not just food-technology filings.
Research Cultivated Meat Cell Lines and Media in depth with Eureka
Go past this page: query the whole cultivated meat cell lines and media corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.